

Amendments to the Claims:

1-118. (canceled)

119. (currently amended) An isolated nucleic acid having at least 80% nucleic acid sequence identity to:

(a) ~~a nucleic acid sequence encoding the polypeptide shown in Figure 109 (SEQ ID NO: 175);~~

(b) ~~a nucleic acid sequence encoding the polypeptide shown in Figure 109 (SEQ ID NO: 175), lacking its associated signal peptide;~~

(c) ~~a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 109 (SEQ ID NO: 175);~~

(d) ~~a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 109 (SEQ ID NO: 175), lacking its associated signal peptide;~~

(e) the nucleic acid sequence of SEQ ID NO: 174 shown in Figure 108 (SEQ ID NO: 174);

(f)(b) the full-length coding sequence of the nucleic acid sequence of SEQ ID NO: 174 shown in Figure 108 (SEQ ID NO: 174); or

(g)(c) the full-length coding sequence of the cDNA deposited under ATCC accession number 203023,

wherein said nucleic acid is amplified in lung tumors.

120. (currently amended) The isolated nucleic acid of Claim 39 having at least 85% nucleic acid sequence identity to:

(a) a nucleic acid sequence encoding the polypeptide of SEQ ID NO: 175 shown in Figure 109 (SEQ ID NO: 175);

(b) a nucleic acid sequence encoding the polypeptide of SEQ ID NO: 175 shown in Figure 109 (SEQ ID NO: 175), lacking its associated signal peptide;

(c) ~~a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 109 (SEQ ID NO: 175);~~

(d) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 109 (SEQ ID NO: 175), lacking its associated signal peptide;

(e) the nucleic acid sequence of SEQ ID NO: 174 shown in Figure 108 (SEQ ID NO: 174);

(f)(d) the full-length coding sequence of the nucleic acid sequence of SEQ ID NO: 174 shown in Figure 108 (SEQ ID NO: 174); or

(g)(e) the full-length coding sequence of the cDNA deposited under ATCC accession number 203023,

wherein said nucleic acid is amplified in lung tumors.

121. (currently amended) The isolated nucleic acid of Claim 39 having at least 90% nucleic acid sequence identity to:

(a) a nucleic acid sequence encoding the polypeptide of SEQ ID NO: 175 shown in Figure 109 (SEQ ID NO: 175);

(b) a nucleic acid sequence encoding the polypeptide of SEQ ID NO: 175 shown in Figure 109 (SEQ ID NO: 175), lacking its associated signal peptide;

(c) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 109 (SEQ ID NO: 175);

(d) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 109 (SEQ ID NO: 175), lacking its associated signal peptide;

(e) the nucleic acid sequence of SEQ ID NO: 174 shown in Figure 108 (SEQ ID NO: 174);

(f)(d) the full-length coding sequence of the nucleic acid sequence of SEQ ID NO: 174 shown in Figure 108 (SEQ ID NO: 174); or

(g)(e) the full-length coding sequence of the cDNA deposited under ATCC accession number 203023,

wherein said nucleic acid is amplified in lung tumors.

122. (currently amended) The isolated nucleic acid of Claim 39 having at least 95% nucleic acid sequence identity to:

(a) a nucleic acid sequence encoding the polypeptide of SEQ ID NO: 175 shown in Figure 109 (SEQ ID NO: 175);

(b) a nucleic acid sequence encoding the polypeptide of SEQ ID NO: 175 shown in Figure 109 (SEQ ID NO: 175), lacking its associated signal peptide;

(c) ~~a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 109 (SEQ ID NO: 175);~~

(d) ~~a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 109 (SEQ ID NO: 175), lacking its associated signal peptide;~~

(e) the nucleic acid sequence of SEQ ID NO: 174 shown in Figure 108 (SEQ ID NO: 174);

~~(f)(d)~~ the full-length coding sequence of the nucleic acid sequence of SEQ ID NO: 174 shown in Figure 108 (SEQ ID NO: 174); or

~~(g)(e)~~ the full-length coding sequence of the cDNA deposited under ATCC accession number 203023,

wherein said nucleic acid is amplified in lung tumors.

123. (currently amended) The isolated nucleic acid of Claim 39 having at least 99% nucleic acid sequence identity to:

(a) a nucleic acid sequence encoding the polypeptide of SEQ ID NO: 175 shown in Figure 109 (SEQ ID NO: 175);

(b) a nucleic acid sequence encoding the polypeptide of SEQ ID NO: 175 shown in Figure 109 (SEQ ID NO: 175), lacking its associated signal peptide;

(c) ~~a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 109 (SEQ ID NO: 175);~~

~~(d) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 109 (SEQ ID NO: 175), lacking its associated signal peptide;~~

(e) the nucleic acid sequence of SEQ ID NO: 174 shown in Figure 108 (SEQ ID NO: 174);

(f)(d) the full-length coding sequence of the nucleic acid sequence of SEQ ID NO: 174 shown in Figure 108 (SEQ ID NO: 174); or

(g)(e) the full-length coding sequence of the cDNA deposited under ATCC accession number 203023,

wherein said nucleic acid is amplified in lung tumors.

124. (currently amended) An isolated nucleic acid comprising:

(a) a nucleic acid sequence encoding the polypeptide of SEQ ID NO: 175 shown in Figure 109 (SEQ ID NO: 175);

(b) a nucleic acid sequence encoding the polypeptide of SEQ ID NO: 175 shown in Figure 109 (SEQ ID NO: 175), lacking its associated signal peptide;

(c) ~~a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 109 (SEQ ID NO: 175);~~

(d) ~~a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 109 (SEQ ID NO: 175), lacking its associated signal peptide;~~

(e) the nucleic acid sequence of SEQ ID NO: 174 shown in Figure 108 (SEQ ID NO: 174);

(f)(d) the full-length coding sequence of the nucleic acid sequence of SEQ ID NO: 174 shown in Figure 108 (SEQ ID NO: 174); or

(g)(e) the full-length coding sequence of the cDNA deposited under ATCC accession number 203023.

125. (currently amended) The isolated nucleic acid of Claim 124 comprising a nucleic acid sequence encoding the polypeptide of SEQ ID NO: 175 shown in Figure 109 (SEQ ID NO: 175).

126. (currently amended) The isolated nucleic acid of Claim 124 comprising a nucleic acid sequence encoding the polypeptide of SEQ ID NO:175 ~~shown in Figure 109 (SEQ ID NO:175)~~, lacking its associated signal peptide.

127-128. (canceled)

129. (currently amended) The isolated nucleic acid of Claim 124 comprising the nucleic acid sequence of SEQ ID NO:174 ~~shown in Figure 108 (SEQ ID NO:174)~~.

130. (currently amended) The isolated nucleic acid of Claim 124 comprising the full-length coding sequence of the nucleic acid sequence of SEQ ID NO:174 ~~shown in Figure 108 (SEQ ID NO:174)~~.

131. (previously presented) The isolated nucleic acid of Claim 124 comprising the full-length coding sequence of the cDNA deposited under ATCC accession number 203023.

132-134. (canceled)

135. (currently amended) A vector comprising the nucleic acid of Claim 124 ~~119~~.

136. (previously presented) The vector of Claim 135, wherein said nucleic acid is operably linked to control sequences recognized by a host cell transformed with the vector.

137. (currently amended) ~~A~~ An isolated host cell comprising the vector of Claim 135.

138. (previously presented) The host cell of Claim 137, wherein said cell is a CHO cell, an *E. coli* or a yeast cell.

139. (new) An isolated nucleic acid molecule at least 20 nucleotides in length that hybridizes under stringent conditions to:

- (a) the nucleic acid sequence of SEQ ID NO:174 or a complement thereof;
- (b) the full-length coding sequence of the cDNA deposited under ATCC accession number 203023 or a complement thereof;

wherein, said stringent conditions use 50% formamide, 5X SSC, 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5X Denhardt's solution, sonicated salmon sperm DNA (50 µg/ml), 0.1% SDS, and 10% dextran sulfate at 42°C, and washes at 42°C in 0.2X SSC, at 55°C in 50% formamide followed by a high-stringency wash at 55°C in 0.1X SSC, EDTA; wherein said isolated nucleic acid molecule is suitable for use as a PCR primer or probe.

140. (new) The isolated nucleic acid molecule of Claim 139 that is at least 50 nucleotides or above in length.

141. (new) The isolated nucleic acid molecule of Claim 139 that is at least 60 nucleotides or above in length.

142. (new) The isolated nucleic acid molecule of Claim 139 that is at least 70 nucleotides or above in length.

143. (New) The isolated nucleic acid molecule of Claim 139 that is at least 80 nucleotides or above in length.

144. (New) The isolated nucleic acid molecule of Claim 139 that is at least 90 nucleotides or above in length.

145. (New) The isolated nucleic acid molecule of Claim 139 that is at least 100 nucleotides or above in length.